Sellas Life Sciences Group's acute myeloid leukemia treatment, SLS009, receives EMA orphan drug designation.

SELLAS Life Sciences Group receives EMA orphan drug designation for acute myeloid leukemia treatment, SLS009, a novel CDK9 inhibitor. This designation offers financial and regulatory incentives, including 10-year marketing exclusivity post-approval and reduced fees protocol assistance. SLS009 has already received FDA orphan drug designation and is currently in Phase 2a clinical trials (NCT04588922).